Catalyst Pharmaceuticals, Inc. (CPRX): Price and Financial Metrics


Catalyst Pharmaceuticals, Inc. (CPRX): $16.38

-0.42 (-2.50%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CPRX POWR Grades

  • CPRX scores best on the Quality dimension, with a Quality rank ahead of 93.3% of US stocks.
  • CPRX's strongest trending metric is Stability; it's been moving down over the last 26 weeks.
  • CPRX ranks lowest in Stability; there it ranks in the 8th percentile.

CPRX Stock Summary

  • For CPRX, its debt to operating expenses ratio is greater than that reported by just 10.19% of US equities we're observing.
  • With a price/sales ratio of 8.93, CATALYST PHARMACEUTICALS INC has a higher such ratio than 87.8% of stocks in our set.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.16 for CATALYST PHARMACEUTICALS INC; that's greater than it is for just 11.3% of US stocks.
  • Stocks that are quantitatively similar to CPRX, based on their financial statements, market capitalization, and price volatility, are PERI, HRMY, DIOD, NTCT, and LVOX.
  • Visit CPRX's SEC page to see the company's official filings. To visit the company's web site, go to www.catalystpharma.com.

CPRX Valuation Summary

  • In comparison to the median Healthcare stock, CPRX's price/earnings ratio is 14.29% higher, now standing at 26.4.
  • Over the past 194 months, CPRX's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for CPRX.

Stock Date P/S P/B P/E EV/EBIT
CPRX 2022-12-05 9.2 6.5 26.4 17.9
CPRX 2022-12-02 9.4 6.7 26.9 18.3
CPRX 2022-12-01 9.0 6.4 25.9 17.5
CPRX 2022-11-30 9.1 6.5 26.1 17.7
CPRX 2022-11-29 8.8 6.3 25.3 17.0
CPRX 2022-11-28 8.9 6.4 25.6 17.3

CPRX Growth Metrics

    Its 2 year revenue growth rate is now at 29.18%.
  • Its 4 year cash and equivalents growth rate is now at 631.98%.
  • Its 3 year revenue growth rate is now at 1087.15%.
Over the past 15 months, CPRX's revenue has gone up $64,853,433.

The table below shows CPRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 191.755 95.146 66.917
2022-06-30 170.465 75.552 54.498
2022-03-31 153.717 65.036 45.06
2021-12-31 140.833 60.372 39.482
2021-09-30 133.5389 54.30157 41.61013
2021-06-30 126.9016 44.04568 74.621

CPRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CPRX has a Quality Grade of B, ranking ahead of 86.8% of graded US stocks.
  • CPRX's asset turnover comes in at 0.656 -- ranking 47th of 682 Pharmaceutical Products stocks.
  • CHRS, XTNT, and BMY are the stocks whose asset turnover ratios are most correlated with CPRX.

The table below shows CPRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.656 0.858 0.924
2021-03-31 0.691 0.854 1.211
2020-12-31 0.773 0.857 2.263
2020-09-30 0.881 0.860 4.875
2020-06-30 1.045 0.857 6.071
2020-03-31 1.175 0.855 2.426

CPRX Price Target

For more insight on analysts targets of CPRX, see our CPRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.30 Average Broker Recommendation 1.5 (Moderate Buy)

CPRX Stock Price Chart Interactive Chart >

Price chart for CPRX

CPRX Price/Volume Stats

Current price $16.38 52-week high $18.39
Prev. close $16.80 52-week low $5.24
Day low $16.37 Volume 1,133,500
Day high $16.82 Avg. volume 1,963,086
50-day MA $14.61 Dividend yield N/A
200-day MA $10.64 Market Cap 1.70B

Catalyst Pharmaceuticals, Inc. (CPRX) Company Bio


Catalyst Pharmaceuticals focuses on the development and commercialization of prescription drugs targeting rare neurological diseases and disorders. The company was founded in 2002 and is based in Coral Gables, Florida.


CPRX Latest News Stream


Event/Time News Detail
Loading, please wait...

CPRX Latest Social Stream


Loading social stream, please wait...

View Full CPRX Social Stream

Latest CPRX News From Around the Web

Below are the latest news stories about CATALYST PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CPRX as an investment opportunity.

If You Invested $1000 in Catalyst Pharmaceutical a Decade Ago, This is How Much It'd Be Worth Now

Holding on to popular or trending stocks for the long-term can make your portfolio a winner.

Yahoo | December 2, 2022

The 7 Best Stocks to Buy on a Dip

The best stocks to buy on a dip can come in many forms, but these seven names look set to deliver outsized returns on a reversal.

Larry Ramer on InvestorPlace | November 29, 2022

10 Robinhood Stocks To Buy That Are Too Cheap To Ignore

In this article, we will be taking a look at 10 Robinhood stocks to buy that are too cheap to ignore. To skip our detailed analysis of these stocks, you can go directly to see the 5 Robinhood Stocks To Buy That Are Too Cheap To Ignore. Robinhood, a commission-free stock trading and investing company, has […]

Yahoo | November 28, 2022

Here is Why Growth Investors Should Buy Catalyst (CPRX) Now

Catalyst (CPRX) possesses solid growth attributes, which could help it handily outperform the market.

Yahoo | November 14, 2022

Are Medical Stocks Lagging Catalyst Pharmaceuticals (CPRX) This Year?

Here is how Catalyst Pharmaceutical (CPRX) and DICE Therapeutics, Inc. (DICE) have performed compared to their sector so far this year.

Yahoo | November 14, 2022

Read More 'CPRX' Stories Here

CPRX Price Returns

1-mo 6.16%
3-mo 10.90%
6-mo 162.92%
1-year 148.56%
3-year 280.93%
5-year 290.00%
YTD 141.95%
2021 102.69%
2020 -10.93%
2019 95.31%
2018 -50.90%
2017 272.38%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.879 seconds.